Y-mAbs Therapeutics, Inc. (YMAB)

Y-mAbs Therapeutics Revenue

Y-mAbs Therapeutics had revenue of $19.53M in the quarter ending June 30, 2025, a decrease of -14.36%. This brings the company's total for the last twelve months to $85.39M, down -1.34% year-over-year. In the year 2024, Y-mAbs Therapeutics had annual revenue of $87.69M with 3.38% growth.

• Revenue (ttm): $85.39M
• Revenue Growth: -1.34%
• P/S Ratio: 4.54
• Revenue / Employee: $821,010
• Employees: 104
• Market Cap: 391.22M

Revenue Chart

Chart

Chart

Revenue by Geography

• United States 65.98M 77.5%
• Eastern Asia 7.46M 8.8%
• Latin America 4.72M 5.5%
• Western Asia 4.05M 4.8%
• Western Europe 2.09M 2.5%
• Other Regions 890.00K 1.0%

Fiscal year ended Dec 31, 2024 See the full Y-mAbs Therapeutics breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2024	87.69M	2.87M	3.38%
Dec 31, 2023	84.82M	19.55M	29.96%
Dec 31, 2022	65.27M	30.37M	87.03%
Dec 31, 2021	34.90M	14.15M	68.18%
Dec 31, 2020	20.75M	-	-

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2025

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jan 1, 2000

Data Sources Report a data error